Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeGuerbetLipiodol® Ultra Fluid for Hysterosalpingography in Women Undergoing Infertility Workup

Lipiodol® Ultra Fluid for Hysterosalpingography in Women Undergoing Infertility Workup

Approoved in Hungary and the Netherlands

Guerbet has received indication approval in Hungary and the Netherlands where Lipiodol® Ultra Fluid is now indicated for hysterosalpingography (HSG) in women undergoing infertility workup. Hungary and the Netherlands are the second and third European countries to grant approval for this indication after Ireland.

HSG is an x-ray procedure during which Lipiodol® Ultra Fluid is slowly infused through a catheter into the uterus to visualizethe fallopian tubes and uterine cavity. Lipiodol® Ultra Fluid is the only oil-soluble contrast medium indicated for HSG. New clinical evidence showing that HSG with Lipiodol® Ultra Fluid enhances pregnancy and live birth rates is now endorsed by Hungary’s National Institute of Pharmacy and Nutrition and the Netherlands’ Medicines Evaluation Board. [1]

Lipiodol® Ultra Fluid is now approved for HSG in women undergoing infertility workup in Ireland, Hungary, and in the Netherlands. In addition to these three countries, Lipiodol® Ultra Fluid is approved for HSG in 12 countries, where Guerbet aims to extend the indication to women undergoing infertility workup. Guerbet also plans to receive authorization for this indication throughout Europe, APAC and Latin America.

“In order to clarify the uncertainty around the use of oil- or water-based contrast for HSG, the H2Oil study, a large randomized trial, in which 1,119 infertile women participated, was conducted in the Netherlands. This landmark study, published in the New England Journal of Medicine, showed significantly 10% more ongoing pregnancies as well as live births in the first six months following HSG with oil-based contrast, as compared to HSG with water-based contrast.1 Publication of the study generated a worldwide renewed interest in tubal flushing and the use of oil-based contrast for HSG. And an economic analysis based on the data of the H2Oil study showed a favorable cost-effectiveness ratio for oil-based contrast compared to water-based contrast for an additional ongoing pregnancy. [2] Thus, there is a strong argument to incorporate tubal flushing with oil-based contrast during HSG in clinical practice”, said Professor Velja Mijatovic, Department of Reproductive Medicine, Amsterdam University Medical Center, on behalf of the H2Oil study group.

Infertility is defined as the inability to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. It is estimated that one in six couples faces infertility issues. [3]

This indication is supported by the positive results of the H2Oil trial, a multicenter, randomized, open-label study, published in The New England Journal of Medicine. In the trial, an HSG performed with Lipiodol® Ultra Fluid significantly increased pregnancy and live birth rates as compared to an HSG performed with a water-based contrast medium. Women were randomly assigned to either HSG with Lipiodol® Ultra Fluid (n=554) or HSG with a water-soluble contrast agent (n=554). After a follow-up of 6 months, the pregnancy rate was 39.7% and 29.1% respectively (rate ratio (RR) 1.37 [1.16; 1.61], p<0.001) and the live birth rate was 38.8% and 28.1% respectively (RR 1.38 [1.17; 1.64], p<0.001).1


References:

[1] Dreyer K et al. Oil-based or water-based contrast for hysterosalpingography in infertile women. N Engl J Med. 2017 May 25;376(21):2043-52.

[2] van Rijswijk J et al. Oil-based or water-based contrast for hysterosalpingography in infertile women: a cost-effectiveness analysis of a randomized controlled trial. Fertil Steril. 2018 Sep;110(4):754-760.

[3] A policy audit on fertility. Analysis of 9 EU countries. March 2017. Fertility Europe.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy